Cours suspendu

Autres langues Decoy Therapeutics Inc. Börse Stuttgart

Actions

FP11

US79400X6022

Recherche biotechnologique et médicale

Temps Différé Börse Stuttgart 17:48:59 14/06/2024			Varia. 5j.	Varia. 1 janv.
3,104 ^EUR	-3,96%		+704,15%	+435,17%

29/09	Decoy Therapeutics, Inc. publie des données pharmacocinétiques précliniques à l’appui d’une administration intranasale hebdomadaire de DCOY-CoV	CI
22/09	Decoy Therapeutics conclut un accord d’incitation à l’exercice de bons de souscription pour 3,85 millions de dollars ; le titre grimpe	MT

Autres langues

30/09	Decoy Therapeutics to Present at The Small Cap Showcase
29/09	Decoy Therapeutics, Inc. Reports Preclinical Pk Data Supporting Once-Weekly Intranasal Administration for Dcoy-Cov
22/09	Decoy Therapeutics Enters Warrant Inducement Deal for $3.85 Million; Shares Rise
22/09	Decoy Therapeutics, Inc. Explores Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
08/09	Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
12/08	Decoy Therapeutics: Q2 Earnings Snapshot
12/08	Decoy Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
27/07	Decoy Therapeutics Demonstrates In Vitro Activity Of D-MAV Candidate Against Wild-Type Ebola Zaire Virus And Opens Exploratory Program To Design D-MAVs Against Filoviruses Including Ebola And Marburg
15/07	Decoy Therapeutics Inc. Elects Patricia Gauthier as Class II Director
10/07	Decoy Therapeutics Files to Register Up to 3.77 Million Shares for Resale
30/06	Top Premarket Decliners
29/06	Top Midday Gainers
29/06	Top Premarket Gainers
27/06	Decoy Therapeutics : Announces Up to $21 Milli...
01/06	Decoy Therapeutics Inc. and hVIVO plc Partner to Advance Lead D-Mav Candidate into the Clinic
26/05	Decoy Therapeutics : Names Brad Pentelute, MIT Profe...
26/05	Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
26/05	Decoy Therapeutics Inc. Announces Appointment of Brad L. Pentelute as Chair of Scientific Advisory Board
11/05	Certain Restricted Stock Units of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026.
11/05	Certain Warrants of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026.
11/05	Certain Stock Options of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026.
11/05	1,051,782 Common Stock of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026.
08/05	Decoy Therapeutics: Q1 Earnings Snapshot
08/05	Decoy Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
27/04	Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston